![]() identify and quantify inter-individual variability and covariate relationships in population PK models.develop structural population PK models to describe the relationships between drug dosing and drug concentration.explain how PK processes are parameterized and how models are used to describe and predict concentration-time profiles.Learning goalsĪfter this part of the course, you will be able to: The model-based simulations can then be used to individualize drug dosing recommendations for these patients, based on their characteristics. With the simulations, we can identify characteristics that can put patients at risk for overdosing, leading to undesired side-effects, or underdosing, leading to therapy failure. Once we have a population PK model that can describe and predict both general trends in the PK of drugs and individual deviations from those trends, we can use model-based simulations to optimize drug dosing. ![]() In a subsequent covariate analysis, potential patient and treatment characteristics that can explain (part of) the inter-individual variability are investigated. An important aspect of population PK modeling is identifying sources of variability between individuals of a population and quantifying this inter-individual variability. With population pharmacokinetic (PK) modeling we describe the concentration-time profile of a drug in the body. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |